Drew Scientific warns of expected first-half loss
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SHARES in Drew Scientific fell almost 10 per cent before rebounding after the newly floated bioscience company warned that it would face a pre-tax loss of about pounds 850,000 halfway, writes Russell Hotten.
The company, whose listing last May was accompanied by bullish comments about rapid growth, discovered reliability problems over a bought-in component for its medical testing equipment.
Drew said the problem had been rectified and shipment of the instruments had been resumed. Legal action for compensation from the American supplier was being considered.
The company, which at the time of the flotation had expected to post an interim profit in December, would now report a loss of about pounds 850,000, Drew said. The company admitted that there had been disappointments since the flotation, but believed that 'the group's potential for rapid growth from 1994 onwards remains strong.'
The shares initially fell 7p to 73p before regaining the loss, probably because the City's initial concern was mellowed by news that Drew had received clearance from the US Food and Drug Administration for its G15 testing equipment.
Clearance in Japan is expected by the end of the year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments